Tango Therapeutics (TNGX) revenue breakdown
By product, Collaboration Revenue is the largest at 71% of fiscal 2024 revenue; License Revenue grew fastest, 161% a year over 3 years.
Revenue by product
Fiscal years, as Tango Therapeutics reports them in its 10-K filings; fiscal 2024 total $42M.
| Products | 2020 | 2021 | 2023 | 2024 | Share |
|---|---|---|---|---|---|
| Collaboration Revenue | $7M | $26M | $32M | $30M | 71% |
| License Revenue | $684,000 | $11M | $5M | $12M | 29% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TNGX.
Open TNGX in InvestinglyQuestions
Where does Tango Therapeutics make its money?
In fiscal 2024, by product: Collaboration Revenue $30M, License Revenue $12M.
From Tango Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.